
ARROWHEAD PHARMACEUTICALS, INC.
100
Recent developments highlight Arrowhead's refinancing activities, clinical progress in RNAi therapeutics including Alzheimer's candidate ARO-MAPT, and ongoing commercial launch efforts for plozasiran.
- Arrowhead Pharmaceuticals became oversold as of November 2026, reflecting market sentiment shifts [N1].
- The company refinanced senior secured term loans with a $400 million credit facility in early November 2026 [N2].
- Positive Phase 1/2a data for Alzheimer's candidate ARO-MAPT showed up to 73% cerebrospinal fluid tau reduction, supporting potential quarterly dosing [N4].
- Arrowhead spotlighted dual-target RNAi data and progress on the commercial launch of plozasiran [N5].
- Weekly industry updates noted Arrowhead's ongoing clinical and regulatory activities alongside other biotech developments [N3].
Arrowhead Pharmaceuticals develops RNAi-based medicines targeting intractable diseases by silencing specific genes. Its TRiM platform enables targeted delivery of siRNA therapeutics to multiple tissues, including liver and central nervous system. The company has a broad pipeline with candidates in various stages from Phase 1 to Phase 3, including wholly-owned and partnered programs. Its first commercial product, REDEMPLO (plozasiran), is approved for Familial Chylomicronemia Syndrome and is under regulatory review for severe hypertriglyceridemia. Arrowhead has collaborations with Novartis, Sarepta, Takeda, GSK, and others, supporting development and commercialization efforts. The company operates research facilities in California and Wisconsin and outsources clinical trial management and manufacturing.
Arrowhead Pharmaceuticals is a biotechnology company specializing in RNA interference therapeutics using its proprietary TRiM platform to silence disease-causing genes. The company has a diversified pipeline with approximately 20 candidates in clinical trials, including its first commercial product REDEMPLO approved for Familial Chylomicronemia Syndrome and progressing regulatory filings for severe hypertriglyceridemia. Arrowhead has established multiple collaborations with major pharmaceutical companies and has strengthened its financial position through recent capital raises. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Arrowhead's RNAi platform addresses a wide range of genetic diseases, including those with limited treatment options. The commercial launch of REDEMPLO and Phase 3 data for plozasiran in severe hypertriglyceridemia indicate clinical and regulatory progress. The expanding pipeline includes multiple candidates in clinical development, such as novel dual-target RNAi molecules and CNS-penetrant therapies, supporting diversification across therapeutic areas. Collaborations with leading pharmaceutical companies provide non-dilutive capital and broaden development and commercialization capabilities.
Arrowhead faces risks common to biotech companies, including clinical trial failures, regulatory hurdles, and commercialization challenges. The company has reported significant net losses and negative earnings per share, reflecting ongoing investment in research and development and commercialization. Dependence on collaborations and milestone payments introduces variability in revenue. The RNAi therapeutic field is competitive, and the ability to achieve broad tissue targeting and long-term safety remains to be fully demonstrated. Market acceptance of RNAi therapies and reimbursement dynamics may impact commercial success.
Arrowhead's moat is based on its proprietary TRiM platform enabling targeted RNAi delivery with potential to address previously undruggable genetic targets. Its broad and versatile RNA chemistry portfolio and ability to silence multiple genes simultaneously provide differentiation. The company's established collaborations with major pharmaceutical firms and its first commercial product approval demonstrate commercial and scientific validation. The platform's ability to target multiple tissues and deliver RNAi therapeutics with improved safety and manufacturing efficiency supports competitive positioning in the RNAi therapeutics field.
• Clinical and Regulatory Risk: Clinical trials may not demonstrate safety or efficacy sufficient for regulatory approval, delaying or preventing commercialization of pipeline candidates.
• Commercialization Risk: Successfully launching and marketing new therapies, including expanding commercial infrastructure for sHTG indication, involves execution risks and market acceptance uncertainties.
• Financial Risk: The company has reported significant net losses and negative EPS, requiring continued capital to fund operations and development programs.
• Collaboration Dependency: Revenue and development progress depend on collaborations and license agreements, which may be subject to changes or termination.
• Competitive and Technological Risk: RNAi therapeutics face competition from other modalities and require continued innovation to maintain differentiation and address safety and delivery challenges.
Business trends: Expansion of RNAi therapeutic pipeline with multiple clinical candidates progressing; commercial launch of REDEMPLO and regulatory filings for sHTG indication; growing collaborations with major pharma.
Execution milestones: Completion of Phase 3 studies SHASTA-3 and SHASTA-4 with positive results; initiation and progress of Phase 1/2a trials for novel candidates including ARO-MAPT and ARO-DIMER-PA; refinancing and capital raises to support operations.
Key risks: Clinical and regulatory uncertainties for pipeline candidates; commercialization execution challenges; financial sustainability amid ongoing net losses; dependency on collaborations; competitive RNAi therapeutic landscape.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Arrowhead Pharmaceuticals specializes in RNA interference therapeutics using its proprietary TRiM platform to silence disease-causing genes.
- The company has approximately 20 candidates in clinical trials across various stages from Phase 1 to Phase 3.
- Its first commercial product, REDEMPLO (plozasiran), is approved for Familial Chylomicronemia Syndrome and is under regulatory review for severe hypertriglyceridemia.
- Arrowhead has collaborations with major pharmaceutical companies including Novartis, Sarepta, Takeda, and GSK.
- The company operates research facilities in California and Wisconsin and outsources clinical trial management and manufacturing.
- Recent developments include refinancing senior secured term loans with a $400 million credit facility and positive Phase 1/2a data for Alzheimer's candidate ARO-MAPT showing up to 73% cerebrospinal fluid tau reduction.
- Arrowhead has highlighted dual-target RNAi data and progress on the commercial launch of plozasiran.
- The company reported significant net losses and negative earnings per share, reflecting ongoing investment in R&D and commercialization.
- Revenue and development progress depend on collaborations and license agreements.
- The RNAi therapeutic field is competitive and requires continued innovation to address safety, delivery, and tissue targeting challenges.
Generated 2026-11-12
- S1 | 2026-11-12 | 10-K
- S2 | 2026-08-04 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Arrowhead Pharmaceuticals Becomes Oversold (ARWR) | https://www.nasdaq.com/articles/arrowhead-pharmaceuticals-becomes-oversold-arwr
- N2 | 2026-11-04 | www.nasdaq.com | Arrowhead Pharmaceuticals, Inc. Refinances Senior Secured Term Loans with $400.0 million Credit Facility | https://www.nasdaq.com/articles/arrowhead-pharmaceuticals-inc-refinances-senior-secured-term-loans-4000-million-credit
- N3 | 2026-10-16 | www.nasdaq.com | Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data | https://www.nasdaq.com/articles/weekly-buzz-rhhby-teva-win-fda-nod-mlab-gsk-cut-jobs-azn-vir-deals-krys-abbv-report-data
- N4 | 2026-10-14 | www.nasdaq.com | Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study | https://www.nasdaq.com/articles/arrowhead-pharmaceuticals-reports-73-csf-tau-reduction-early-aro-mapt-study
- N5 | 2026-09-19 | www.nasdaq.com | Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress | https://www.nasdaq.com/articles/arrowhead-pharmaceuticals-spotlights-dual-target-rnai-data-plozasiran-launch-progress
- N6 | 2026-09-18 | www.nasdaq.com | Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands | https://www.nasdaq.com/articles/arrowhead-pharmaceuticals-eyes-shtg-filing-rnai-pipeline-expands
- N7 | 2026-08-06 | www.nasdaq.com | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | https://www.nasdaq.com/articles/sareptas-q2-earnings-sales-beat-estimates-26-outlook-updated
- N8 | 2026-08-04 | www.nasdaq.com | Arrowhead Pharmaceuticals Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/arrowhead-pharmaceuticals-q3-earnings-call-highlights
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


